Balstilimab

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer

EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery

Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas

The Seven Trial: Exploiting the Unfolded Protein Response

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)

Combination Immunotherapy in Colorectal Cancer

Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial

Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Botensilimab, Balstilimab, and SBRT in Colorectal Cancer

BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients

Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas